Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0HN8P
|
|||
| Drug Name |
Leronlimab
|
|||
| Synonyms |
PRO 140
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 2 | [1], [2] | |
| Therapeutic Class |
Antiviral Agents
|
|||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN C-C chemokine receptor 5 (CCR5) | Target Info | Inhibitor | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04343651) Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19 | |||
| REF 2 | Leronlimab Shows Further Promise for COVID-19 Treatment, Study Shows. May 09, 2020 | |||
| REF 3 | Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.